Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 1, 2011, Pages 77-83

  Ferrari, Paolo ^a,c   Kulkarni, Hemant ^a   Dheda, Shyam ^a   Betti, Susanne ^a   Harrison, Colin ^b   St Pierre, Timothy G ^a   Olynyk, John K ^b,c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FERRITIN; FERROSIG; IRON POLYMALTOSE; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIALYSIS; DRUG MEGADOSE; FEMALE; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HEMODIALYSIS; HUMAN; IRON DEPLETION; IRON OVERLOAD; IRON THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; STATISTICAL SIGNIFICANCE; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TRANSFERRIN;

EID: 79251526560     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04190510     Document Type: Article

References (38)

1. Carter RA, Hawkins JB, Robinson BH: Fe metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron. BMJ 3: 206-210, 1969
2. Milman N: Fe absorption measured by whole body counting and the relation to marrow Fe stores in chronic uremia. Clin Nephrol 17: 77-81, 1982
3. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and Fe in haemodialysis patients. Nephrol Dial Transplant 19: 141-149, 2004
4. Roger S: The CARI guidelines. Haematological targets. Iron Nephrol (Carlton) 11[Suppl 1]: S217-S229, 2006
5. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47: S11-S145, 2006
6. Charytan C, Qunibi W, Bailie GR: Comparison of intravenous Fe sucrose to oral Fe in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100: c55-c62, 2005
7. Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H: Clinical use of the total dose intravenous infusion of Fe dextran. J Lab Clin Med 111: 566-570, 1988
8. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of Fe supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996
9. Taylor JE, Peat N, Porter C, Morgan AG: Regular lowdose intravenous Fe therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11: 1079-1083, 1996
10. Kalantar-Zadeh K, Lee GH: The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 1[Suppl 1]: S9-S18, 2006
11. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between Fe and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070-3080, 2005
12. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R: Noninvasive measurement and imaging of liver Fe concentrations using proton magnetic resonance. Blood 105: 855-861, 2005 (Pubitemid 40070775)
13. Cartwright GE, Edwards CQ, Kravitz K, Skolnick M, Amos DB, Johnson A, Buskjaer L: Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 301: 175-179, 1979
14. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739-761, 1997
15. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B: Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 12: 444-454, 2009
16. Lenth RV: Statistical power calculations. J Anim Sci 85: E24-E29, 2007
17. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A: Validation of serum ferritin values by magnetic susceptometry in predicting Fe overload in dialysis patients. Kidney Int 65: 1091-1098, 2004
18. St Pierre TG, Clark PR, Chua-Anusorn W: Single spinecho proton transverse relaxometry of iron-loaded liver. NMR Biomed 17: 446-458, 2004
19. Olynyk JK, Gan E, Tan T: Predicting Fe overload in hyperferritinemia. Clin Gastroenterol Hepatol 7: 359-362, 2009
20. Papakonstantinou OG, Maris TG, Kostaridou V, Gouliamos AD, Koutoulas GK, Kalovidouris AE, Papavassiliou GB, Kordas G, Kattamis C, Vlahos LJ, Papavassiliou CG: Assessment of liver Fe overload by T2-quantitative magnetic resonance imaging: correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis. Magn Reson Imaging 13: 967-977, 1995
21. Clark PR, St Pierre TG: Quantitative mapping of transverse relaxivity (1/T(2)) in hepatic Fe overload: A single spin-echo imaging methodology. Magn Reson Imaging 18: 431-438, 2000
22. Clark PR, Chua-Anusorn W, St Pierre TG: Proton transverse relaxation rate (R2) images of liver tissue: Mapping local tissue Fe concentrations with MRI. Magn Reson Med 49: 572-575, 2003
23. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV Fe sucrose to oral Fe in anemic patients with nondialysis-dependent CKD. Kidney Int 68: 2846-2856, 2005
24. Polkinghorne K, McDonald S, Excell L, Livingston B, Dent H: Ferritin and transferrin saturation. 2009 ANZDATA Registry Annual Data Report. Available at: http://www.anzdata.org.au/anzdata/AnzdataReport/32ndReport/Ch05.pdf. Accessed August 27, 2010
25. Murray MJ, Murray AB, Murray MB, Murray CJ: The adverse effect of Fe repletion on the course of certain infections. BMJ 2: 1113-1115, 1978
26. Seifert A, von Herrath D, Schaefer K: Fe overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65: 1015-1024, 1987
27. Bregman H, Gelfand MC: Fe overload in patients on maintenance hemodialysis. Int J Artif Organs 4: 56-57, 1981
28. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Fe therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217, 2002
29. Gokal R, Millard PR, Weatherall DJ, Callender ST, Ledingham JG, Oliver DO: Fe metabolism in haemodialysis patients. A study of the management of Fe therapy and overload. Q J Med 48: 369-391, 1979
30. Rogers J, Lacroix L, Durmowitz G, Kasschau K, Andriotakis J, Bridges KR: The role of cytokines in the regulation of ferritin expression. Adv Exp Med Biol 356: 127-132, 1994
31. Harrison PM, Arosio P: The ferritins: Molecular properties, Fe storage function and cellular regulation. Biochim Biophys Acta 1275: 161-203, 1996
32. Ferrari P, Mallon D, Trinder D, Olynyk JK: Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology 15: 344-349, 2010
33. Bossola M, Sanguinetti M, Scribano D, Zuppi C, Giungi S, Luciani G, Torelli R, Posteraro B, Fadda G, Tazza L: Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol 4: 379-385, 2009
34. Samouilidou EC, Grapsa EJ, Kakavas I, Lagouranis A, Agrogiannis B: Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol 35: 393-397, 2003
35. Xue JL, Dahl D, Ebben JP, Collins AJ: The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 42: 1013-1019, 2003
36. Bassett ML, Halliday JW, Ferris RA, Powell LW: Diagnosis of hemochromatosis in young subjects: Predictive accuracy of biochemical screening tests. Gastroenterology 87: 628-633, 1984
37. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of Fe overload in patients with thalassemia major. N Engl J Med 331: 567-573, 1994
38. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD: MRI R2 and R2* mapping accurately estimates hepatic Fe concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106: 1460-1465, 2005